BioCryst Pharmaceuticals
BCRX
#4438
Rank
โ‚ฌ2.04 B
Marketcap
8,15ย โ‚ฌ
Share price
-3.34%
Change (1 day)
44.24%
Change (1 year)

BioCryst Pharmaceuticals (BCRX) - Total liabilities

Total liabilities on the balance sheet as of December 2025 : โ‚ฌ0.53 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's total liabilities are โ‚ฌ0.53 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BioCryst Pharmaceuticals - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2025-12-31โ‚ฌ0.53 B-41.95%
2024-12-31โ‚ฌ0.92 B5.56%
2023-12-31โ‚ฌ0.87 B11.73%
2022-12-31โ‚ฌ0.78 B28.28%
2021-12-31โ‚ฌ0.61 B113.28%
2020-12-31โ‚ฌ0.28 B135.27%
2019-12-31โ‚ฌ0.12 B43.37%
2018-12-31โ‚ฌ85.32 M8.34%
2017-12-31โ‚ฌ78.75 M-6.15%
2016-12-31โ‚ฌ83.91 M22.94%
2015-12-31โ‚ฌ68.25 M35.56%
2014-12-31โ‚ฌ50.35 M39.1%
2013-12-31โ‚ฌ36.19 M-17.29%
2012-12-31โ‚ฌ43.76 M-15.67%
2011-12-31โ‚ฌ51.9 M57.1%
2010-12-31โ‚ฌ33.03 M-15.36%
2009-12-31โ‚ฌ39.03 M42.61%
2008-12-31โ‚ฌ27.37 M-48.64%
2007-12-31โ‚ฌ53.29 M48.57%
2006-12-31โ‚ฌ35.86 M4.13%
2005-12-31โ‚ฌ34.44 M1390.89%
2004-12-31โ‚ฌ2.31 M76.48%
2003-12-31โ‚ฌ1.3 M16.78%
2002-12-31โ‚ฌ1.12 M-56.62%
2001-12-31โ‚ฌ2.58 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Gilead Sciences
GILD
โ‚ฌ31.03 B 5,648.36%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚ฌ51.85 B 9,503.59%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sarepta Therapeutics
SRPT
โ‚ฌ1.88 B 248.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
โ‚ฌ0.71 B 33.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
โ‚ฌ1.11 B 105.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
โ‚ฌ47.59 M-91.19%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
โ‚ฌ1 M-99.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
โ‚ฌ10.4 M-98.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
โ‚ฌ0.74 B 38.72%๐Ÿ‡บ๐Ÿ‡ธ USA